Amgen hit as UK suspends Tavneos for new patients
Amgen faces a widening regulatory threat to rare-disease drug Tavneos. The U.K. suspended use for new patients and set a path toward full withdrawal in March 2027, after similar Europe action and proposed U.S. withdrawal.
Amgen NASDAQ:AMGN is facing a widening regulatory threat to rare-disease drug Tavneos, after the U.K. suspended its use for new patients and set a path toward full withdrawal in March 2027.
The decision follows similar action in Europe and a proposed U.S. withdrawal, raising the risk that a fast-gr…